The Traf2- and Nck-interacting protein kinase (TNIK) inhibitor NCB-0846 was found to enhance cell death induced by the BCL-X(L) inhibitor ABT-263 in KRAS/BRAF mutant cells, which may be a new combination treatment strategy for the KRAS/BRAF-mutant CRC [80]. Here, KRAS is linked to colorectal carcinoma.